Gilead Deepens R&D Investment with US$10 B Galapagos Deal

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 7 (Table of Contents)

Published: 19 Jul-2019

DOI: 10.3833/pdr.v2019.i7.2440     ISSN: 1756-7874

Section: Licensing



In its largest deal of 2019 so far, Gilead Sciences has signed a 10-year collaboration with Galapagos to gain the license and option rights to all current and future Galapagos programmes in all countries outside Europe for a total deal value of up to US$9...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details